Levallois-Perret, France

David Sourdive

USPTO Granted Patents = 7 

 

 

Average Co-Inventor Count = 4.2

ph-index = 2

Forward Citations = 48(Granted Patents)


Company Filing History:


Years Active: 2010-2025

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: The Innovations of David Sourdive

Introduction

David Sourdive, an accomplished inventor based in Levallois-Perret, France, has made significant contributions to the field of immunotherapy, boasting a portfolio of seven patents. His pioneering work is redefining approaches to cancer treatment, particularly through the innovative engineering of T-cells.

Latest Patents

Sourdive's latest patent revolves around a method for generating T-cells that are compatible for allogenic transplantation. This invention introduces engineered T-cells designed for immunotherapy. The engineered T-cells are notable for their inhibited expression of beta 2-microglobulin (B2M) and class II major histocompatibility complex transactivator (CIITA). This inhibition can be achieved by utilizing rare-cutting endonucleases that selectively inactivate the genes encoding B2M and/or CIITA, or through nucleic acid molecules that suppress their expression.

Another recent patent focuses on cellular immunotherapy for repetitive administration. This invention includes composition kits and methods aimed at treating cancer in humans through immunotherapy using successive doses of CAR-T cells that exhibit no or reduced anamnestic immune reaction in individual patients, enhancing treatment efficacy.

Career Highlights

David Sourdive's tenure at Cellectis marks a significant chapter in his career, where he has actively contributed to revolutionary advancements in cellular therapy. His expertise in genetic engineering and immunology has positioned him as a key player in developing innovative solutions in the medical field.

Collaborations

Throughout his career, Sourdive has collaborated with esteemed colleagues such as Philippe Duchateau and Jean-Pierre Cabaniols. These partnerships have played a vital role in enriching his research and enhancing the impact of his inventions.

Conclusion

David Sourdive's inventive spirit and dedication to advancing cancer treatment through immunotherapy are undeniably shaping the future of therapeutic interventions. With seven patents to his name and ongoing collaborations with prominent professionals, he exemplifies the innovative ethos that drives the medical field forward.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…